Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a Jerusalem, Israel-based biopharmaceutical company operating two complementary business units: Scinai R&D, focused on developing innovative inflammation and immunology (I&I) therapeutics based on nanosized VHH antibody fragments (NanoAbs) targeting diseases with large unmet medical needs, and Scinai Bioservices, a boutique contract development and manufacturing organization (CDMO) providing analytical method development, process development, and clinical cGMP manufacturing services to early-stage biotech clients worldwide. The company holds key licensing and collaboration agreements with the Max Planck Society and the University Medical Center Göttingen for the development and commercialization of NanoAb candidates, and has demonstrated growing commercial traction with CDMO revenues reaching $1.05 million for the first nine months of 2025, up from $452,000 in the prior-year period. Formerly known as BiondVax Pharmaceuticals Ltd., the company rebranded to Scinai Immunotherapeutics Ltd. in September 2023 and has since expanded its footprint by establishing a U.S.-based subsidiary, Scinai Bioservices Inc., to further scale its CDMO operations. Founded in 2003 and listed on the NASDAQ Capital Market since 2015, Scinai employs approximately 45 full-time staff and continues to advance a diversified pipeline targeting autoimmune and infectious diseases.